Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Shahneen Sandhu(Peter MacCallum Cancer Centre), Thomas Müller(490 BioTech (United States)), Sarah M. McWhirter(490 BioTech (United States)), Omid Hamid(Memorial Sloan Kettering Cancer Center), Shailender Bhatia(University of Washington), Toshio Shimizu(Kansai Medical University), Neeltje Steeghs(Peter MacCallum Cancer Centre), Lisa Kattenhorn(American Institutes for Research), Nitya Nair(490 BioTech (United States)), Agostina Stradella(Institut Català d'Oncologia), Jason J. Luke(UPMC Hillman Cancer Center), Georgina V. Long(Westmead Hospital), Randy F. Sweis(National Cancer Institute), Marc R. Pelletier(American Institutes for Research), Andrew Bean(Tris Pharma (United States)), Nancy Lewis(Tris Pharma (United States)), Anna Spreafico(Princess Margaret Cancer Centre), Stefan Kasper(Essen University Hospital), Reinhard Dummer(University of Zurich), Xinhui Chen(Novartis (Switzerland))
Cited by 226
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k